SKP2 and acute lymphoblastic leukemia: SKP2 inhibitors with better pharmacological profile have the potential to be highly effective in T-ALL, and likely in other cancers, as SKP2 expression has been shown to correlate with progression in different tumors and blood malignancies (review in [45]).